Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma

Pediatr Blood Cancer. 2018 Oct;65(10):e27271. doi: 10.1002/pbc.27271. Epub 2018 Jun 12.

Abstract

Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6-NTRK fusion, which constitutively activates the tropomyosin-related kinase (TRK) signaling pathway. Larotrectinib is a highly selective TRK inhibitor with activity in adult and pediatric patients who have TRK fusions. We present a rare case of a patient with mesoblastic nephroma metastatic to bone who had a dramatic response to larotrectinib.

Keywords: ETV6-NTRK; TRK inhibitor; bone metastasis; larotrectinib; mesoplastic nephroma.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / genetics
  • Bone Neoplasms / secondary
  • Bone Remodeling / drug effects*
  • Humans
  • Infant
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / genetics
  • Kidney Neoplasms / pathology
  • Male
  • Nephroma, Mesoblastic / drug therapy*
  • Nephroma, Mesoblastic / genetics
  • Nephroma, Mesoblastic / secondary
  • Oncogene Proteins, Fusion / genetics
  • Pyrazoles / therapeutic use*
  • Pyrimidines / therapeutic use*

Substances

  • Antineoplastic Agents
  • ETV6-NTRK3 fusion protein, human
  • Oncogene Proteins, Fusion
  • Pyrazoles
  • Pyrimidines
  • larotrectinib